Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies

By Jain Nitin   Odenike Olatoyosi  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 3073-3084

Informa Healthcare

Access to resources Recommend Favorite

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

By Acharya Milin   Karp Judith   Sausville Edward   Hwang Kyunghwa   Ryan Qin   Gojo Ivana   Venitz Jűrgen   Figg William   Sparreboom Alex  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 367-375

Springer Publishing Company

Access to resources Recommend Favorite

Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells

By Oh Eun-Taex  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 435-442

Springer Publishing Company

Access to resources Recommend Favorite

Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species

By  

Drug Metabolism Letters, Vol. 1, Iss. 2, 2007-04 ,pp. : 153-161

Bentham Science Publishers

Access to resources Recommend Favorite

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl- XL

By Hwang Jung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1434-1442

Springer Publishing Company

Access to resources Recommend Favorite